Literature DB >> 29037086

Measles and rubella elimination: learning from polio eradication and moving forward with a diagonal approach.

James L Goodson1, James P Alexander1, Robert W Linkins1, Walter A Orenstein2.   

Abstract

INTRODUCTION: In 1988, an estimated 350,000 children were paralyzed by polio and 125 countries reported polio cases, the World Health Assembly passed a resolution to achieve polio eradication by 2000, and the Global Polio Eradication Initiative (GPEI) was established as a partnership focused on eradication. Today, following eradication efforts, polio cases have decreased >99% and eradication of all three types of wild polioviruses is approaching. However, since polio resources substantially support disease surveillance and other health programs, losing polio assets could reverse progress toward achieving Global Vaccine Action Plan goals. Areas covered: As the end of polio approaches and GPEI funds and capacity decrease, we document knowledge, experience, and lessons learned from 30 years of polio eradication. Expert commentary: Transitioning polio assets to measles and rubella (MR) elimination efforts would accelerate progress toward global vaccination coverage and equity. MR elimination feasibility and benefits have long been established. Focusing efforts on MR elimination after achieving polio eradication would make a permanent impact on reducing child mortality but should be done through a 'diagonal approach' of using measles disease transmission to identify areas possibly susceptible to other vaccine-preventable diseases and to strengthen the overall immunization and health systems to achieve disease-specific goals.

Entities:  

Keywords:  Elimination; eradication; immunizations; measles; polio; rubella; vaccine-preventable diseases

Mesh:

Year:  2017        PMID: 29037086      PMCID: PMC6477920          DOI: 10.1080/14760584.2017.1393337

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  9 in total

1.  Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation.

Authors:  Suyash Deodhar; Brady Sillman; Aditya N Bade; Sean N Avedissian; Anthony T Podany; JoEllyn M McMillan; Nagsen Gautam; Brandon Hanson; Bhagya L Dyavar Shetty; Adam Szlachetka; Morgan Johnston; Michellie Thurman; Daniel J Munt; Alekha K Dash; Milica Markovic; Arik Dahan; Yazen Alnouti; Alborz Yazdi; Bhavesh D Kevadiya; Siddappa N Byrareddy; Samuel M Cohen; Benson Edagwa; Howard E Gendelman
Journal:  Nat Commun       Date:  2022-06-09       Impact factor: 17.694

2.  School-based delivery of routinely recommended vaccines and opportunities to check vaccination status at school, a global summary, 2008-2017.

Authors:  Leora R Feldstein; Garrett Fox; Abigail Shefer; Laura M Conklin; Kirsten Ward
Journal:  Vaccine       Date:  2019-11-01       Impact factor: 3.641

3.  Accelerating measles and rubella elimination through research and innovation - Findings from the Measles & Rubella Initiative research prioritization process, 2016.

Authors:  Gavin B Grant; Balcha G Masresha; William J Moss; Mick N Mulders; Paul A Rota; Saad B Omer; Abigail Shefer; Jennifer L Kriss; Matt Hanson; David N Durrheim; Robert Linkins; James L Goodson
Journal:  Vaccine       Date:  2019-03-20       Impact factor: 3.641

4.  Measles and rubella IgG seroprevalence in persons 6 month-35 years of age, Mongolia, 2016.

Authors:  Francisco Nogareda; Nyamaa Gunregjav; Amarzaya Sarankhuu; Enkhtuya Munkhbat; Enkhbaatar Ichinnorov; Pagbajabyn Nymadawa; Kathleen Wannemuehler; Mick N Mulders; Jose Hagan; Minal K Patel
Journal:  Vaccine       Date:  2020-05-04       Impact factor: 3.641

5.  Studies into the mechanism of measles-associated immune suppression during a measles outbreak in the Netherlands.

Authors:  Brigitta M Laksono; Rory D de Vries; R Joyce Verburgh; Eline G Visser; Alwin de Jong; Pieter L A Fraaij; Wilhemina L M Ruijs; David F Nieuwenhuijse; Henk-Jan van den Ham; Marion P G Koopmans; Menno C van Zelm; Albert D M E Osterhaus; Rik L de Swart
Journal:  Nat Commun       Date:  2018-11-23       Impact factor: 14.919

Review 6.  A microneedle patch for measles and rubella vaccination: a game changer for achieving elimination.

Authors:  Mark R Prausnitz; James L Goodson; Paul A Rota; Walter A Orenstein
Journal:  Curr Opin Virol       Date:  2020-07-01       Impact factor: 7.090

7.  Policy and practice of checking vaccination status at school in 2018, a global overview.

Authors:  Katrin Sadigh; Garrett Fox; Nino Khetsuriani; Hongjiang Gao; Stephanie Shendale; Kirsten Ward
Journal:  Vaccine       Date:  2022-03-17       Impact factor: 4.169

8.  Prevalence and management of rubella susceptibility in healthcare workers in Italy: A systematic review and meta-analysis.

Authors:  Francesco Paolo Bianchi; Pasquale Stefanizzi; Giusy Diella; Andrea Martinelli; Antonio Di Lorenzo; Maria Serena Gallone; Silvio Tafuri
Journal:  Vaccine X       Date:  2022-08-07

Review 9.  Global trends in measles publications.

Authors:  Rachel Kornbluh; Robert Davis
Journal:  Pan Afr Med J       Date:  2020-02-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.